Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-10-25
1998-01-06
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514913, A61K 31445
Patent
active
057055106
ABSTRACT:
The use of certain dopaminergic compounds for controlling elevations of intraocular pressure is disclosed. The compounds are ergoline derivatives. The most preferred compound is cabergoline. The compounds have been found to produce a significant reduction of intraocular pressure.
REFERENCES:
patent: 4501749 (1985-02-01), Clineschmidt
patent: 4526892 (1985-07-01), Salvati et al.
patent: 4722933 (1988-02-01), Horn
patent: 4728649 (1988-03-01), Mantegani et al.
patent: 4774243 (1988-09-01), Baldwin
patent: 4847253 (1989-07-01), Buonamici et al.
patent: 4861793 (1989-08-01), Bernardi et al.
patent: 5110606 (1992-05-01), Geyer
patent: 5151272 (1992-09-01), Engstrom et al.
Elibol, O., et al., Intl. Ophthalmology, "The effects of dopamine, haloperidol and bromocriptine on intraocular pressure", vol. 16, pp. 343-347 (1992).
Green, et al., Exp. Eye Res., "Dopamine Stimulation of Passive Permeability and Secretion in the Isolated Rabbit Ciliary Epithelium", vol. 29, pp. 423-427 (1979).
Macri, et al., Exp. Eye Res., "The Inhibitory Actions of Dopamine, Hydroxyamphetamine and Phenylephrine on Aqueous Humor Formation", vol. 26, pp. 85-89 (1978).
Mekki, et al., The Lancet, "Bromocriptine Lowers Intraocular Pressure Without Affecting Blood Pressure", pp. 1250-1251 (1983).
Potter, et al., Curr Eye Res., "Effects of ergoline derivatives on intraocular pressure and iris function in rabbits and monkeys", vol. 2, pp. 281-288 (1983).
Potter, et al., Curr. Eye Res., "Alteration in ocular function induced by phenylethylamine analogs of dopamine", vol. 3, pp. 851-859 (1984).
Shanon, et al., Investigative Ophthalmology, "The effect of dopamine on the intraocular pressure and pupil of the rabbit eye", vol. 15, pp. 371-380 (1976).
Hutton, J. T., et al., Neurology, "Controlled study of the antiparkinsonian activity and tolerability of cabergoline", vol. 43, pp. 613-616 (1993).
Karnezis, T. A., et al., Trends In Pharmacological Science, "Dopamine receptors and intraocular pressure", vol. 9, No. 11, pp. 389-390 (1988).
Potter, D. E., et al., Current Eye Research, "Ocular hypotensive action of ergoline derivatives in rabbits: effects of sympathectomy and domperidone pretreatment", vol. 3, No. 2, pp. 307-314 (1984).
Siegal, M. J., et al., Experimental Eye Research, "Effect of Topical Pergolide on Aqueous Dynamics in Normal and Glaucomatous Monkeys", vol. 44, No. 2, pp. 227-233 (1987).
Potter, D. E., et al. Journal Of Ocular Pharmacology, "LY141865: A Relatively Selective DA.sub.2 Agonist with Complex Ocular Activity", vol. 4, No. 1, pp. 19-28 (1988).
Potter, D. E., et al., Journal of Ocular Pharmacology, "Cianergoline Lowers Intraocular Pressure in Rabbits and Monkeys and Inhibits Contraction of the Cat Nictitans by Suppressing Sympathetic Neuronal Function", vol. 3, No. 4, pp. 309-321 (1987).
Al-Sereiti, et al., Proceedings of the BPS, "The effects of a single oral dose of lisuride, terguride and bromocriptine on intraocular pressure", vol. 9, No. 11, p. 122P (Sep. 1987).
Geyer, et al., Journal of Ocular Pharmacology, "Hypotensive Effect of Bromocriptine in Normal Eyes", vol. 3, No. 1, pp. 1-4 (1987).
Geyer, et al., Journal of Ocular Pharmacology, "Hypotensive Effect of Bromocriptine in Glaucomatous Eyes", vol. 3, No. 4, pp. 291-294 (1987).
Al-Sereiti, et al., Br. J. clin. Pharmac., "A comparison of the ocular hypotensive effect of 0.025% bromocriptine and 0.25% timolol eye drops in normal human volunteers", vol. 28, pp. 443-447 (1989).
Mekki, et al., British Journal of Ophthalmology, "Stimulation of dopamine receptors (type 2) lowers human intraocular pressure", vol. 69, pp. 909-910 (1985).
Al-Sereiti, et al., Br. J. clin. Pharmac., "The effect of a single oral dose of pergolide on intraocular pressure and pupil diameter", vol. 28, pp. 263-268 (1989).
Al-Sereiti, et al., Br. J. clin. Pharmac., "The effects of lisuride, terguride and bromocriptine on intraocular pressure (IOP)", vol. 27, pp. 159-163 (1989).
DeSantis, Jr. Louis
Maniar Manoj L.
McLaughlin Marsha A.
Sallee Verney L.
Alcon Laboratories Inc.
Brown Gregg C.
Fay Zohreh
Mayo Michael C.
LandOfFree
Use of cabergoline and related ergoline derivatives for controll does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of cabergoline and related ergoline derivatives for controll, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of cabergoline and related ergoline derivatives for controll will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2329390